Search results
Results from the WOW.Com Content Network
The negotiations with Johnson & Johnson were led by Frans Van den Bergh, head of the board of directors. On 10 February 1964, the name was changed to Janssen Pharmaceutica N.V. and the seat of the company in Turnhout was also transferred to Beerse. The company was led by Paul Janssen, Bob Stouthuysen and Frans Van Den Bergh. When, in 1971 to ...
Chairman of the Board of Directors of Janssen Pharmaceutica Ajit, Baron Shetty [ 1 ] is a Belgian businessman. [ 2 ] He was chairman of the board of directors of Janssen Pharmaceutica , a pharmaceutical company and subsidiary of Johnson & Johnson , with its headquarters in Beerse , Belgium .
The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, [1] is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, [24] and its Belgian parent company Janssen Pharmaceuticals, [25] a subsidiary of American company Johnson & Johnson.
J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011 [2] [3] and delisting the company from stock exchanges two months later. [4] After the takeover by Johnson & Johnson in 2011, Crucell was assigned to Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed from Crucell to Janssen ...
After the death of Naegeli in 1942, Joos himself then took over the managing role until he left the company in 1949. [1] In 1959, Cilag joined the Johnson & Johnson family of companies. In the early 1990s, the marketing organizations of Cilag and Janssen Pharmaceuticals were joined to form Janssen-Cilag. The non-marketing activities of both ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
All declined comment on that question, and despite being independent board members, technically unaffiliated with the company, all referred me to J&J’s public relations department. But Michael Johns , a board member, physician and former chancellor of Emory, did say, “As I understand it, Risperdal was a drug that treats symptoms of a ...
The company was sentenced to pay a fine of $6.14 million. [4] Ortho-McNeil's parent company, Johnson and Johnson, also paid $75.37 million to resolve civil allegations under the False Claims Act that it caused false claims to be submitted to government health care programs for a variety of psychiatric uses that were not FDA approved. [4]